|Application / Reactivity||Dog (Canine)|
|Chromatin Immunoprecipitation (ChIP)||1 Antibodies|
|Flow Cytometry (FACS)||1 Antibodies|
|Immunocytochemistry (ICC)||5 Antibodies|
|Immunofluorescence (IF)||6 Antibodies|
|Immunohistochemistry (IHC)||5 Antibodies|
|Immunohistochemistry (Frozen Sections) (IHC (fro))||1 Antibodies|
|Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))||5 Antibodies|
|Immunoprecipitation (IP)||5 Antibodies|
|Western Blotting (WB)||7 Antibodies|
|Antigen||Baculoviral IAP Repeat-Containing 5 (BIRC5) Antibodies|
|Reactivity||Dog (Canine) Alternatives|
|Conjugate||This BIRC5 antibody is un-conjugated Alternatives|
Chromatin Immunoprecipitation (ChIP), Immunocytochemistry (ICC), Flow Cytometry (FACS), Immunohistochemistry (Frozen Sections) (IHC (fro)), Immunofluorescence (IF), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunoprecipitation (IP), Immunohistochemistry (IHC), ELISA, Western Blotting (WB)
|15 references available|
|Supplier||Log in to see|
Product Details anti-BIRC5 AntibodyTarget Details BIRC5 Application Details Handling References for anti-BIRC5 Antibody (ABIN153009) Images
|Immunogen||Full length recombinant human Survivin|
Target Details BIRC5Product Details anti-BIRC5 Antibody Application Details Handling References for anti-BIRC5 Antibody (ABIN153009) Images back to top
|Alternative Name||IAP4 / BIRC5 (BIRC5 Antibody Abstract)|
Regulated inhibition of programmed cell death (apoptosis) preserves normalhomeostasis and tissue and organ morphogenesis. Aberrations in this processcontribute to human diseases and cancer by abnormally prolonging cell viability. Recently, several apoptosis inhibitors related to the baculovirus iap gene have beenfound in various species, including human. IAP proteins contain one/three Cys/Hisbaculovirus IAP repeats plus a C-terminal RING finger and are thought to block anevolutionary conserved step in apoptosis.Survivin encodes a structurally unique inhibitor of apoptosis (IAP). Survivin expressionis turned off during fetal development and is not found in non-neoplastic adult humantissues. Survivin becomes abundantly re-expressed in transformed cells and in all ofthe most common cancers of lung, colon, pancreas, breast and prostate in vivo. Survivin appears to be situated at the crossroads of cell death and cell division,governing a checkpoint involved in cytokinesis while also suppressing apoptosis. Survivin is also abundantly expressed in brain tissues (astrocytes and some neurons) ofadult rats following traumatic brain injury. Survivin has been found co-expressed withNeuN (mature neuronal marker) and PCNA (a cell cycle protein). Survivin might affectregulation of neural cell proliferative responses after brain injury. Alternate Names: anti-API4 antibody, anti-Apoptosis Inhibitor 4 antibody, anti-Apoptosis inhibitor survivinantibody, anti-Baculoviral IAP repeat containing 5 antibody, anti-BIRC 5 antibody,anti-EPR 1 antibody, anti-IAP4 antibody, anti-SVV antibody, anti-TIAP antibody,anti-BIRC5 antibody.
Gene Symbol: BIRC5
|Gene ID||332, 11799, 64041|
|Research Area||Cancer, Apoptosis/Necrosis, Neurology|
|Pathways||Apoptosis, Cell Division Cycle|
Application DetailsProduct Details anti-BIRC5 Antibody Target Details BIRC5 Handling References for anti-BIRC5 Antibody (ABIN153009) Images back to top
This Survivin antibody is useful for Chromatin Immunoprecipitation, Immunocytochemistry/Immunofluorescence, Immunohistochemistry on paraffin-embedded sections, Immunoprecipitation and Western Blot. In WB, a band at ~16.5 kDa can be seen. For IHC, prior antigen retrieval (pressure cooking) is recommended for cytoplasmic and nuclear detection of Survivin. Immunohistochemistry-Frozen and Flow Cytometry were reported in scientific literature.
Recommended dilutions: Chromatin Immunoprecipitation 1:10-1:500, ELISA, Flow Cytometry, Immunocytochemistry/Immunofluorescence 1:50-1:250, Immunohistochemistry 1:50-1:100, Immunohistochemistry-Frozen, Immunohistochemistry-Paraffin 1:50-1:500, Immunoprecipitation 1:10-1:500, Western Blot 1 µg/mL
|Protocol||Western Blot Protocol Specific for Survivin Antibody Western Blot Procedure1) Cells were pelleted, washed in 1XPBS, suspended in ice water (~ 5 x 10(6) cells/ml), and placed on ice2) Lysates were prepared with the addition of 2X lysis buffer [2 % SDS/ 50mM Tris-HCl / 10 % glycerol]3) Lysates were heated to 95 degrees C for 3 minutes and then microfuged at room temperature for 10 minutes4) 50 µg of lysate were electrophoresed (150 V) through a 4-15 % PAGE5) Proteins were transferred (60 V) onto an Immobilon-P membrane (Millipore Corp.) for 45 minutes6) The blot was blocked overnight at 4 degrees C in blocking buffer [1XPBS, pH 7 / 5 % nonfat milk / 0.1 % Tween-20]7) Washed the blot in 1XPBS / 0.1 % Tween-208) Incubated the blot with 1 µg/ml of anti-Survivin antibody, diluted in blocking buffer, for 2 hours at room temperature9) Washed the blot in 1XPBS / 0.1 % Tween-2010) Reacted the blot with HRP-conjugated donkey anti-rabbit Ig, diluted in 1XPBS / 0.1 % Tween-20, for 30 minutes at room temperature11) Washed the blot in 1XPBS / 0.1 % Tween-2012) Visualized blot by ECL and autoradiographyNOTE: HeLa whole cell extracts were used as a positive control for this antibody.|
|Restrictions||For Research Use only|
HandlingProduct Details anti-BIRC5 Antibody Target Details BIRC5 Application Details References for anti-BIRC5 Antibody (ABIN153009) Images back to top
|Buffer||Tris-glycine, 150 mM NaCl, Sodium Azide|
|Precaution of Use||WARNING: Reagents contain sodium azide. Sodium azide is very toxic if ingested or inhaled. Avoid contact with skin, eyes, or clothing. Wear eye or face protection when handling. If skin or eye contact occurs, wash with copious amounts of water. If ingested or inhaled, contact a physician immediately. Sodium azide yields toxic hydrazoic acid under acidic conditions. Dilute azide-containing compounds in running water before discarding to avoid accumulation of potentially explosive deposits in lead or copper plumbing.|
|Handling Advice||Avoid freeze-thaw cycles|
|Storage Comment||Aliquot and store at -20 °C or -80 °C.|
References for anti-BIRC5 Antibody (ABIN153009)Product Details anti-BIRC5 Antibody Target Details BIRC5 Application Details Handling Images back to top
|Product cited in:||
Blanc-Brude, Mesri, Wall et al.: "Therapeutic targeting of the survivin pathway in cancer: initiation of mitochondrial apoptosis and suppression of tumor-associated angiogenesis." in: Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 9, Issue 7, pp. 2683-92, 2003 (PubMed).
Hauf, Cole, LaTerra et al.: "The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore-microtubule attachment and in maintaining the spindle assembly checkpoint." in: The Journal of cell biology, Vol. 161, Issue 2, pp. 281-94, 2003 (PubMed).
Kennedy, ODriscoll, Purcell et al.: "Prognostic importance of survivin in breast cancer." in: British journal of cancer, Vol. 88, Issue 7, pp. 1077-83, 2003 (PubMed).
Miranda, Dyer, Grandis et al.: "Differential activation of apoptosis regulatory pathways during monocytic vs granulocytic differentiation: a requirement for Bcl-X(L)and XIAP in the prolonged survival of monocytic cells." in: Leukemia, Vol. 17, Issue 2, pp. 390-400, 2003 (PubMed).
Grabowski, Kuehnel, Muehr-Wilkenshoff et al.: "Prognostic value of nuclear survivin expression in oesophageal squamous cell carcinoma." in: British journal of cancer, Vol. 88, Issue 1, pp. 115-9, 2003 (PubMed).
Mahotka, Liebmann, Wenzel et al.: "Differential subcellular localization of functionally divergent survivin splice variants." in: Cell death and differentiation, Vol. 9, Issue 12, pp. 1334-42, 2002 (PubMed).
Blanc-Brude, Yu, Simosa et al.: "Inhibitor of apoptosis protein survivin regulates vascular injury." in: Nature medicine, Vol. 8, Issue 9, pp. 987-94, 2002 (PubMed).
Yu, Leung, Ebert et al.: "Increased expression of survivin in gastric cancer patients and in first degree relatives." in: British journal of cancer, Vol. 87, Issue 1, pp. 91-7, 2002 (PubMed).
Zhang, Hazarika, Ni et al.: "Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action." in: Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 8, Issue 5, pp. 1234-40, 2002 (PubMed).
Giodini, Kallio, Wall et al.: "Regulation of microtubule stability and mitotic progression by survivin." in: Cancer research, Vol. 62, Issue 9, pp. 2462-7, 2002 (PubMed).
Zeitlin, Shelby, Sullivan: "CENP-A is phosphorylated by Aurora B kinase and plays an unexpected role in completion of cytokinesis." in: The Journal of cell biology, Vol. 155, Issue 7, pp. 1147-57, 2001 (PubMed).
Zhu, Fukuda, Cordis et al.: "Anti-apoptotic protein survivin plays a significant role in tubular morphogenesis of human coronary arteriolar endothelial cells by hypoxic preconditioning." in: FEBS letters, Vol. 508, Issue 3, pp. 369-74, 2001 (PubMed).
Fortugno, Wall, Giodini et al.: "Survivin exists in immunochemically distinct subcellular pools and is involved in spindle microtubule function." in: Journal of cell science, Vol. 115, Issue Pt 3, pp. 575-85, 2002 (PubMed).
Chakravarti, Noll, Black et al.: "Quantitatively determined survivin expression levels are of prognostic value in human gliomas." in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 20, Issue 4, pp. 1063-8, 2002 (PubMed).
Wheatley, Carvalho, Vagnarelli et al.: "INCENP is required for proper targeting of Survivin to the centromeres and the anaphase spindle during mitosis." in: Current biology : CB, Vol. 11, Issue 11, pp. 886-90, 2001 (PubMed).
ImagesProduct Details anti-BIRC5 Antibody Target Details BIRC5 Application Details Handling References for anti-BIRC5 Antibody (ABIN153009) back to top